Myeloproliferative neoplasm
Disease3 papers
- Human trial1
- Animals1
Trial sponsors
Company1 trialPhase 185 people
3 trialsPhase 3367 people
2 trialsPhase 2251 people
Ottawa Hospital Research Institute
1 trialPhase 244 people
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
1 trialPhase 235 people
Case Comprehensive Cancer Center
1 trialPhase 212 people
1 trialPhase 1/284 people
Roswell Park Alliance Foundation, Roswell Park Comprehensive Cancer Center
1 trialPhase 1/235 people
Funding
National Cancer InstituteUS$1.6m3 grants since 2022
Cell Competition in Myeloproliferative Neoplasms
National Cancer InstituteState University New York Stony BrookUS$362.3k2022–2027
Selective pressures from inherited variation impacting myeloproliferative neoplasm initiation
National Cancer InstituteBoston Children's HospitalUS$508k2022–2027
National Cancer InstituteRhode Island HospitalUS$688.9k2026–2031
Latest
7Metformin linked to fewer clots in blood cancer and diabetes
Metformin users had lower blood clot risk than non-users, with a hazard ratio of 0.78, a measure comparing risk over time.Metformin users had lower blood clot risk than non-users, with a hazard ratio of 0.78, a measure comparing risk over time.